NTLA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Intellia Therapeutics Inc (NTLA) does not present a strong buy opportunity for a beginner, long-term investor at this time. While the FDA lifting the clinical hold on its MAGNITUDE studies is a positive catalyst, the company's financial performance shows significant losses, insiders are selling heavily, and technical indicators do not suggest a clear upward trend. Additionally, the stock lacks strong trading signals from Intellectia Proprietary Trading Signals, and options data indicates a bearish sentiment. Given these factors, holding off on investment is the prudent choice.
The MACD is below 0 and negatively contracting, indicating bearish momentum. RSI is neutral at 52.724, and moving averages are converging, showing no clear trend. The stock is trading near its pivot level of 13.233, with key resistance at 13.796 and support at 12.67. Overall, the technical indicators suggest a lack of strong directional movement.
The FDA lifted the clinical hold on the MAGNITUDE Phase 3 study, allowing enrollment to resume. Analysts have raised price targets, with some firms upgrading the stock to Buy or Outperform. The company's gross margin remains at 100%, indicating strong operational efficiency.
Insiders have been selling heavily, with a 2235.78% increase in selling activity over the last month. The company reported a significant net income loss of -$95.79M in Q4 2025, with EPS dropping by -34.65% YoY. Technical indicators and options data suggest bearish sentiment, and there is no recent news or congress trading data to provide additional positive momentum.
In Q4 2025, revenue increased by 78.79% YoY to $23.02M, but net income dropped by -25.69% YoY to -$95.79M. EPS fell to -0.83, a decline of -34.65% YoY. While the gross margin remains at 100%, the overall financial performance indicates significant challenges in profitability.
Analysts have generally reacted positively to the FDA lifting the clinical hold, with multiple firms raising price targets (ranging from $15 to $48) and upgrading ratings. However, some analysts remain cautious due to safety concerns and competitive therapeutic alternatives. The consensus view is cautiously optimistic but not overwhelmingly bullish.
